+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

BRCA1 and EGFR as prognostic biomarkers in triple negative metastatic breast cancer patients treated with cisplatin plus docetaxel



BRCA1 and EGFR as prognostic biomarkers in triple negative metastatic breast cancer patients treated with cisplatin plus docetaxel



Chinese-German Journal of Clinical Oncology 9(12): 700-707




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 063891775

Download citation: RISBibTeXText

DOI: 10.1007/s10330-010-0699-x


Related references

Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology 24(5): 1219-1225, 2013

Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis. Biomed Research International 2015: 357485, 2015

Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 19(3): 246-248, 2010

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. Bmc Cancer 7: 203, 2007

Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer. Oncology Letters 7(1): 278-284, 2014

Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients. Zhonghua Yi Xue Za Zhi 96(12): 940-943, 2016

Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients. Targeted Oncology 9(4): 349-357, 2014

Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. Journal of Clinical Oncology 31(20): 2586-2592, 2013

Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer. Cancer Investigation 36(7): 378-388, 2018

Prognostic analysis of patients with metastatic triple-negative breast cancer: a report of 120 cases. Zhonghua Yi Xue Za Zhi 90(40): 2848-2851, 2010

A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes. Cancer Biology and Therapy 16(12): 1746-1753, 2015

MiR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer. Breast Cancer Research 16(5): 435, 2014

Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients. American Journal of Nuclear Medicine and Molecular Imaging 6(2): 120-127, 2016

Efficacy and safety of cisplatin plus capecitabine for patients with metastatic triple negative breast cancer progressing after anthracycline and taxane treatment. Zhonghua Zhong Liu Za Zhi 37(12): 938-941, 2015

Gemcitabine Plus Docetaxel Versus Docetaxel in Patients With Predominantly Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer A Randomized, Phase III Study by the Danish Breast Cancer Cooperative Group Breast. 2011